Decreased CD5+B cells in active ANCA vasculitis and relapse after rituximab

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 3, 2013, Pages 382-391

  O'Dell Bunch, Donna ^a   McGregor, Julieanne G ^a   Khandoobhai, Nirmal B ^a,b   Aybar, Lydia T ^a   Burkart, Madelyn E ^a   Hu, Yichun ^a   Hogan, Susan L ^a   Poulton, Caroline J ^a   Berg, Elisabeth A ^a   Falk, Ronald J ^a   Nachman, Patrick H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; BIOPSY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RELAPSE; REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS; SMALL VESSEL VASCULITIS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD5; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENOTYPE; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875026249     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03950412     Document Type: Article

References (38)

1. Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318: 1651-1657, 1988
2. Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 337: 1512-1523, 1997
3. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002
4. Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS: Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS ONE 7: e28626, 2012
5. McQueen F: A B cell explanation for autoimmune disease: The forbidden clone returns. Postgrad Med J 88: 226-233, 2012
6. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, SpecksU; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010
7. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010
8. Berland R, Wortis HH: Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20: 253-300, 2002
9. Soldevila G, Raman C, Lozano F: The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Curr Opin Immunol 23: 310-318, 2011
10. Youinou P, Renaudineau Y: The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev 7: 149-154, 2007
11. Youinou P, Renaudineau Y: The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 114: 363-369, 2004
12. Hippen KL, Tze LE, Behrens TW: CD5 maintains tolerance in anergic B cells. J Exp Med 191: 883-890, 2000
13. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C: CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32: 129-140, 2010
14. Iwata Y, Matsushita T, HorikawaM, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117: 530-541, 2011
15. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, AduD: BirminghamVasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87: 671-678, 1994
16. Novack SN, Pearson CM: Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 284: 938-942, 1971
17. Nachman PH, Hogan SL, Jennette JC, Falk RJ: Treatment response and relapse in antineutrophil cytoplasmic autoantibodyassociated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7: 33-39, 1996
18. Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M, Fertmann R, Reinhold-Keller E: Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63: 257-266, 2011
19. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH: Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum 58: 2908-2918, 2008
20. Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L: Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49: 2181-2190, 2010
21. Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D; European Vasculitis Study Group: Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64: 542-548, 2012
22. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA: Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford) 51: 100-109, 2012
23. Kä lsch AI, Csernok E, Münch D, Birck R, Yard BA, Gross W, Kä lsch T, Schmitt WH: Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis. J Rheumatol 37: 2319-2325, 2010
24. Finkielman JD, Merkel PA, SchroederD, HoffmanGS, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Lears AK, Ytterberg SR, Hummel AM, Viss MA, Peikert T, Stone JH, Specks U; WGET Research Group: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity inWegener granulomatosis. Ann Intern Med 147: 611-619, 2007
25. Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA: Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 63: 3988-3997, 2011
26. TomassonG, LavalleyM, Tanriverdi K, Finkielman JD, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Stone JH, Freedman JE, Merkel PA; Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol 38: 1048-1054, 2011
27. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH: Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 100: 4537-4543, 2002
28. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P: CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 186: 4835-4844, 2011
29. O'Garra A, Chang R, Go N, Hastings R, HaughtonG, Howard M: Ly-1 B (B-1) cells are themain source of B cell-derived interleukin 10. Eur J Immunol 22: 711-717, 1992
30. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF: A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650, 2008
31. Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, Damoiseaux J: Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. J Neuroimmunol 239: 80-86, 2011
32. Youinou P, Mackenzie LE, Lamour A, Mageed RA, Lydyard PM: Human CD5-positive B cells in lymphoid malignancy and connective tissue diseases. Eur J Clin Invest 23: 139-150, 1993
33. Kim HS, Noh GW, Kim DS, Lee KY, Lee HS, Lee HK, Lee SI: Decreased CD5+ B cells during the acute phase of Kawasaki disease. Yonsei Med J 37: 52-58, 1996
34. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I: B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 122: 139-145, 2007
35. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54: 613-620, 2006
36. Roll P, Dörner T, Tony HP: Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58: 1566-1575, 2008
37. Rhee EP, Laliberte KA, Niles JL: Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5: 1394-1400, 2010
38. Garaud S, Le Dantec C, deMendoza AR, Mageed RA, Youinou P, Renaudineau Y: IL-10 production by B cells expressing CD5 with the alternative exon 1B. Ann N Y Acad Sci 1173: 280-285, 2009